State Bank of India Regulatory Approval

Other Announcement

State Bank of India Other Announcement

State Bank of India submitted a security cover certificate for the quarter ended September 30, 2026. The certificate confirms nil security cover as the listed debt securities are unsecured.

Earnings Call

State Bank of India Investor Presentation: Key Takeaways

Q2FY27 net profit ₹23,038 Cr (+14.28% YoY), operating profit ₹34,226 Cr (+7.28%), NII +14.69%. GNPA 1.39%, CRAR 16.09%. Profit includes one-time gains.

Results Update

State Bank of India Results Update

SBI's Q2FY27 PAT grew 14.28% YoY to ₹23,038 crore. Advances and deposits reached ₹52 and ₹63 trillion respectively.

Financial Results

State Bank of India Q2 FY27 Results: Net Profit ₹25,361 Cr, Up 20.0% YoY

State Bank of India reported revenue from operations of ₹141,073 Cr (+10.3% YoY) and net profit of ₹25,361 Cr (+20.0% YoY) for Q2 FY27.

Key figure

Net profit ₹25,361 Cr · +20.0% YoY

Debt & Borrowing

State Bank of India Debt & Borrowing: ₹781 Cr

SBI paid ₹781 Crore annual interest on its Basel III Tier 2 bonds on 2 November 2026. No delay or change in payment frequency was reported.

Value

₹781.0 Cr

Debt & Borrowing

State Bank of India Debt & Borrowing: ₹399 Cr

State Bank of India paid ₹399 Crore annual interest on its AT1 bond series INE062A08462. Payment was made on October 26, 2026 after holiday shifts.

Value

₹399.0 Cr

Regulatory ApprovalWanbury Ltd WANBURYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Regulatory ApprovalSandur Manganese & Iron Ores Ltd SANDUMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Regulatory ApprovalNeogen Chemicals Ltd NEOGENAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Regulatory ApprovalArihant Capital Markets Ltd ARIHANTCAPAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.